Abstract: A surgical table arm support assembly and surgical table therewith is provided. The assembly includes a mount bracket and an upright support member operably attached to the mount bracket. A lateral support member is operably attached to the upright support member. The lateral support member is selectively movable about 3 axes. An arm support member is operably attached to the lateral support member. The arm support member is selectively movable about 3-axes. The arm support member can be precisely positioned and releasably fixed in the desired position to best assure the patient's arm, which is releasably fixed to the arm support member, is properly supported and located over the course of a lengthy surgical procedure to minimize the risk of trauma resulting from the arm being supported in a rearward extending, elevated position.

Abstract: A relaxation device comprising: a resting platform having a generally planar surface; a frame assembly supporting the resting platform; the frame assembly having at least one rail extending along an axis oriented along the width of the resting platform; a frame support for supporting the frame assembly above the ground, the frame support having a rail guide extending along an axis oriented along the width of the resting platform, the at least one rail slidably mounted to the rail guide; and a cam assembly having a cam, a cam arm, a cam guide and a motor, the cam guide fixedly mounted to the at least one rail, the cam guide having a slot extending orthogonal to the at least one rail, the slot defining a cam path, the cam mounted to a distal end of the cam arm, the cam operatively disposed within the slot, the motor mechanically connected to the cam arm so as to rotate the cam arm, wherein the cam is moved along the cam path further moving the at least one rail between opposing ends of the rail guide so as to m

Abstract: An air pulse generator provides a high frequency chest wall oscillation therapy to a patient wearing an inflatable garment. The air pulse generator includes a blower and a valve coupled to the blower and coupled to the inflatable garment. The valve is movable to apply an oscillating pressure to the inflatable garment. The valve may be a rotary valve or a solenoid valve.

Abstract: A massage device includes a body which contains motor and massage head, where installation mechanism is located between the body and the massage head and said head includes application surface and two massage wheels located along two initial parallel longitudinal axes, which are separated and extend partially outside the application surface. The massage head includes to cause the two wheels to rotate in synchronization and in opposite directions so that, when seen in perpendicular plane to the two axes with the wheels toward the bottom, section of wheel located on the left which extends past the application surface turns counterclockwise and section of wheel located on the right which extends past the application surface turns clockwise. A wheel spacing adjustment system is designed to initially create a minimum distance between the wheels then to adjust the distance to reach a position of equilibrium.

Abstract: A massage roller device includes a body having a tube and an outer layer. The tube is rigid and includes a receiving portion having two openings. A first coupling portion is provided in each opening. The outer layer is made of a soft material and is mounted around the tube. The massage roller device further includes two covers made of a rigid material are provided. Each cover covers one of the openings of the body. Each cover includes a lid having an inner side and an outer side opposite to the inner side. A second coupling portion is provided on the inner side of each lid. Two engagement pegs are formed on the outer side of each lid. Two engagement grooves are defined in the outer side of each lid.

Abstract: Techniques associated with an implant system for imparting vibratory massage to tissue within a body is disclosed. In some examples, a device includes a case having an engaging surface configured to conform to a surface of a bladder, a passage extending from an opening on the case to another opening on the case, the passage configured to receive a securing member, a vibration generator coupled to the case and configured to generate a vibration, and a power receiver coupled to the case, the power receiver having a receiving coil and configured to receive electrical energy from a remote source.

Abstract: The coupling includes drive and driven hubs. The drive hub is mounted to a rotating element and has a surface presenting away therefrom. In the absence of externalities, a magnetic field is produced wherein, if depicted graphically, concentrations of field lines extend from two or more North pole domains defined in the surface to two or more South pole domains defined in the surface, the domains being spaced apart and encircling the rotation axis in alternating relation. The driven hub is disposed in spaced, frontwardly adjacent relation to the drive hub, is fixed to the rotatable element and is at least substantially constrained against movement but for rotation with the rotatable element. The driven hub includes: a rotor body of a non-magnetic, electrically-conductive material having relatively low magnetic permeability; and a flux ring of material having a relatively high magnetically permeability arranged in spaced relation to the body.

Abstract: A container includes a chamber to hold a medication, a lockable lid that covers an opening of the chamber, a biometric sensor, a scale, and one or more processors. The container may store prescription information indicating how often the medication should be provided. The container may measure a weight of the medication held by the chamber using the scale. The container may receive biometric information sensed by the biometric sensor. The biometric information may indicate a biometric feature of a person attempting to open the container. The container may selectively unlock the lockable lid based on at least one of the prescription information, the weight of the medication, or the biometric information.

Abstract: A device for taking samples from containers includes: a receiving body for at least one container; a container bar code reader positioned in the receiving body for containers; a support for a test tube with the ability to move; a bar code reader positioned in the support; and a fluid communication component between the container and the test tube. The support for test tubes includes at least a test tube loading position and a sample-taking position. The device also includes a controller configured to control position of the support for test tube. The controller can also include at least one sensor of the position of the support for test tube and a blocking component configured to block a position of said support for test tube.

Abstract: A syringe includes a plunger having a plunger tube with proximal and distal ends, a center tube with a center passage that extends within the plunger tube, and a balloon disposed over the center tube and sealingly fixed to at least one of the center tube and the plunger tube. The syringe also includes a barrel having a barrel tube having proximal and distal ends and an interior configured to accept a portion of the plunger, a tip fixedly coupled to the proximal end of the barrel tube, a post fixedly attached to the tip and extending within the barrel tube toward the distal end, the tip configured to partially extend into the center passage of the plunger, and a gas passage extending from a proximal end of the tip to the distal end of the post.

Abstract: An internal bolster for use securing a medical device, such as a feeding tube, within a body of a patient is disclosed. In one embodiment, a feeding tube includes an internal bolster, comprising one or more bolster arms that each include a first end hingedly connected to a distal end of the medical device and a free second end. The bolster arms are selectively deployable between a first position wherein the bolster arms are substantially in-line with an axis of feeding tube, and a second position wherein the bolster arms are substantially deflected from the axis of the feeding tube to enable securement of the feeding tube within a stoma or other opening defined in the body. Various means for selectively moving the bolster arms between the first and second positions are disclosed. Related methods of use are also disclosed.

Abstract: A medical port assembly having a body assembly with a top wall, a bottom wall, first and second walls, and an interior wall. The body assembly further has an exterior wall and an interior adhesive wall. The interior adhesive wall has adhesive means. A permeable wall comprises a slit protected by an overlapping flap. The interior wall and the permeable wall define a cavity. A protective cover covers the interior adhesive wall and/or the cavity. The protective cover adheres to the adhesive. A feeding tube is positioned through the slit. The feeding tube has a distal end, an external retention ring, and at least one port defined as a feeding port, a medication port, or a fluid port. When not utilized, the feeding tube is stored within the cavity.

Abstract: A composition of matter includes one or more functionalized vinylbenzyl components of the formula covalently connected to one or more R functional components; the one or more R functional groups selected from a group including one or more hydroxyl methyl (—CHOH—) moieties and/or derivatives thereof, one or more ethoxy (—CH2—CH2—O—) moieties and/or derivatives thereof, and one or more benzene (C6H6) and/or derivatives thereof; and ether links that connect the functionalized vinylbenzyl components and the R functional components.

Abstract: Topically applicable, stable, transparent self-tanning aqueous gels, suited for artificially tanning and/or browning human skin, contain at least one self-tanning agent and at least one water-soluble or water-dispersible, crosslinked or non-crosslinked (co)polymerizate of at least the acrylamido-2-methylpropanesulfonic acid (AMPS) monomer, or partially or totally neutralized form thereof, formulated into a topically applicable, cosmetically acceptable support therefor.

Abstract: The present invention is directed to a granulated composition comprising a salt encapsulated by a composition that comprises at least one wax.

Abstract: Described herein are methods of cleaning a tooth comprising administering a composition comprising a zinc amino acid halide complex to the oral cavity; and retaining the composition in the oral cavity for a time sufficient to form a precipitate.

Abstract: Oxygen therapy for healthy or inflamed but intact skin involves placing an oxygen-generating dressing onto the skin to be treated, the oxygen-generating bandage being a one-time use dressing capable of generating oxygen for only a short period of time, not to exceed about 4 hours.

Abstract: Activated aluminum sesquichlorohydrate (AASCH) powders and method of making are disclosed. The AASCH powder has Al:Cl atomic ratio of from about 1.60 to about 1.90 and Band III polymer concentration of at least about 20% and Band IV polymer concentration of at least about 15% when analyzed with Size Exclusion Chromatogram (SEC) operated by High Performance Liquid Chromatograph (HPLC). The method of making the active comprises (a) diluting the concentrated aluminum sesquichlorohydrate (ASCH) solution to from about 10% to about 25% by weight and (b) heating the diluted solution to obtain a Band III polymer concentration of at least about 20% and a Band IV polymer concentration of at least about 15%, and (c) drying the heated solution to powders having Al:Cl ratio of about 1.60 to about 1.90 and (d) optionally screen or light mill the powders to free flowing spherical particles.

Abstract: The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high total amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation.

Abstract: The present invention relates to novel uses of compounds from Antrodia cinnamomea mycelia and mixtures comprising the compounds. The novel uses comprise whitening skin, combating skin ageing, reducing scar formation, inducing or enhancing liver regeneration, or treating fibrosis or a fibrosis-associated disorder in a subject in need thereof. The compounds have the formula and preferably are selected from 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]furan-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-1-ol-2,5-dione, 3R*,4S*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione, and 3R*,4R*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione.

Abstract: The present invention is directed to a method for straightening hair, wherein the method of straightening hair comprises the step of: (1) applying to the hair a hair treatment composition comprising: i) gluconolactone, in which the level of gluconolactone is from 1.5 to 5 wt % of the total hair treatment composition; and ii) citric acid, in which the level of citric acid is from 1 to 5 wt % of the total hair treatment composition; and (2) applying heat to the hair at a temperature of greater than 120° C. for at least 10 seconds after the hair treatment composition is applied to the hair, wherein the hair treatment composition is applied to dry hair.

Abstract: A dentifrice composition containing a polyethylene glycol having an average molecular weight of from about 3,000 to about 8,000, glycerin, precipitated silica, and a fluoride source. The polyethylene glycol forms a crystalline structure in the composition and the composition has a water activity from about 0.25 to about 0.46 measured at about 22° C.

Abstract: To provide a water-in-oil emulsion composition having a high stability and which provides fresh feeling in use and glossy finish. The water-in-oil emulsion composition of the present invention is characterized by comprising: (a) 1 to 20 mass % of a polyhydric alcohol fatty acid ester and/or a hydrocarbon; (b) 3 to 20 mass % of a transparent non-volatile silicone oil that separates when mixed with component (a) at 25° C.; (c) 0.1 to 5 mass % of zinc decyl trisiloxanecarboxylate; and (d) water.

Abstract: The present invention concerns a composition comprising a physiologically acceptable medium containing perlite and at least one vinyl polymer bearing at least one carbosiloxane dendrimer-based unit. The composition is used in the care of and for making up the skin, in particular to provide a matt effect.

Abstract: Disclosed is a composition for preventing hair loss or promoting hair restoration and for enhancing hair health, the composition comprising an active ingredient in the form of soy extract extracted using a C1 to C5 alcohol at a concentration of between 1% and 70% (v/v).

Abstract: Described herein is a polyherbal composition effective in skin care, including singularly or in certain combinations 0.01% to 15% of Ziziphus extract, 0.01% to 10% of Prunus extract, suitable delivery system, and a suitable carrier.

Abstract: The present invention features novel cosmetic skin care compositions for improving the appearance of skin.

Abstract: The invention refers to a cosmetic composition for increasing collagen synthesis in skin cells comprising 0.001-0.5 wt % of a Phaeodactylum tricornutum extract, 0.00001-2.0 wt % of Dimer Tripeptide-43 or Hydrolyzed Rice Protein, and cosmetic auxiliaries. The cosmetic composition comprising the combination of both components has an synergistic effect on collagen I synthesis in skin cells and has a booster effect to other substances which are known to have an enhancing effect to collagen I synthesis.

Abstract: Provided are a polymer/liposome nanocomposite composition comprising lipids and poly(amino acids), and a method for preparing same. The polymer/liposome nanocomposite composition has excellent formation stability with respect to surfactants and salts, and can be used in various ways as a drug delivery system in the fields of medicine and cosmetics.

Abstract: The present invention is directed to a suitable topical composition for cosmetic, pharmaceutical or dermatological use. In a particular aspect, it is a stable nanoemulsion whose particles have a narrow size distribution range. In another particular aspect, the invention is directed to an improved process for producing said composition.

Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.

Abstract: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.

Abstract: The layered drug delivery devices of the present invention have an outer side and an inner side. The device includes, in order from the outer side to the inner side, a first layer and a second layer. The first layer wherein the first layer is water insoluble, water swellable, and water permeable. The second layer includes a therapeutic amount of a water soluble drug and a water soluble mucoadhesive film. The second layer is disposed such that water passing through said first layer solubilizes the drug. The said solubilized drug then can permeate through a mucosal membrane when the inner side is in contact with the mucosal membrane. The drug delivery device is in sheet form.

Abstract: Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided.

Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

Abstract: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.

Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.

Abstract: A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders.

Abstract: The present invention relates to a novel use of xanthophylls, particularly astaxanthin and/or an ester thereof, for inhibiting tumor cell growth. Therefore, the present invention provides a method for preventing or treating cancers, comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of at least one type of xanthophyll.

Abstract: Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.

Abstract: The invention provides compositions and methods for inhibiting renal fibrosis.

Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.

Abstract: The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2, with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2, and kits for practicing the assay method.

Abstract: The present invention provides a pharmaceutical composition for delivering an active agent taxane through transmucosal administration, more particularly through the buccal mucosa or sublingual mucosa. The present invention provides a method for treating cancer by buccal or sublingual administration of the pharmaceutical composition to a subject. The pharmaceutical composition comprises a taxane, a non-ionic surfactant, a viscosity enhancing agent, an adhesive agent, and an alcohol solvent at pH 4-6.